Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities

Beactica Therapeutics AB, the Swedish precision oncology company, announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors.